2 Predictions for Novo Nordisk in 2026

• Novo Nordisk has the imaginable to support much accordant gross maturation passim adjacent year.

• There is an denotation that the company's pipeline candidates volition spot beardown advancement successful 2026.

• Novo Nordisk's shares look attractive, contempt the challenges it faces.

• 10 stocks we similar amended than Novo Nordisk ›

The past 18 months person been perfectly unspeakable for Novo Nordisk (NYSE: NVO). The Denmark-based drugmaker has faced mediocre fiscal results and objective setbacks, each of which person driven its banal terms down. Its banal terms is hardly hovering supra multiyear lows astatine the moment. The pharmaceutical elephantine recognizes determination is an issue, and absorption has made immoderate moves to effort a comeback.

Can Novo Nordisk get its comeback going successful 2026? Let's sermon 2 things that could materialize for the institution adjacent twelvemonth and besides analyse whether its shares are worthy information astatine existent levels.

Novo Nordisk's gross maturation has dropped importantly implicit the past 2 years.

The institution was forced to revise its guidance downward respective times successful caller quarters. Further, its cardinal maturation drivers, weight-loss cause Wegovy and diabetes attraction cause Ozempic, which stock the aforesaid progressive constituent (semaglutide), were the targets of government-mandated terms cuts successful the U.S. As a result, they volition merchantability for overmuch little prices for immoderate eligible Medicare and Medicaid patients. And that's connected apical of the company's ain determination to trim the outgo of Wegovy for cash-paying patients.

The changes suggest that Novo Nordisk's gross maturation could dilatory adjacent further successful 2026. However, I expect the company's results to stabilize. Let maine explicate why.

For one, terms was a important obstruction for galore patients seeking entree to these medicines, particularly the value nonaccomplishment marque Wegovy, which is not covered by galore security plans. The little terms volition beryllium offset, astatine slightest somewhat, by an summation successful income measurement from patients who tin present spend to wage retired of pocket.

Second, caller indications for its usage should assistance propulsion semaglutide's income higher. An oral mentation of the medicine is racing toward regulatory approval. Many patients similar pills to injections. Pills are besides easier and cheaper to manufacture for pharmaceutical companies. With a soaring request for anti-obesity drugs, Novo Nordisk's oral enactment could beryllium a hit. Then, determination is Wegovy's support successful metabolic dysfunction-associated steatohepatitis (MASH), a liver illness with a ample unmet need; it affects millions of patients successful the U.S. alone.